• Introduction to Myeloma
  • News
  • Multiple Myeloma Q&A
  • Testimonials
  • Press Releases
  • Resources
  • Biography
  • Resume
  • Contact
Subscribe: Posts | Comments
James R. Berenson, MD, Inc. Berenson Oncology
  • Introduction to Myeloma
  • News
  • Multiple Myeloma Q&A
  • Testimonials
  • Press Releases
  • Resources
  • Biography
  • Resume
  • Contact
RSS

Updates on Treatment

December 18, 2014

Press Releases, Videos

“How do you know if you are getting the right drugs at the right doses for treating your myeloma?”

About admin

View all posts by admin →

Subscribe

Subscribe to our e-mail newsletter to receive updates.

Related Posts:

  • Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
  • IMBCR & Emory University’s Big Discovery!!!
  • James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
  • Video Updates
  • Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
← Year End 2014
Talking About Myeloma with Loved Ones →

Comments are closed.

James R. Berenson, MD

James R. Berenson, MD

  • President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
  • President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
  • Founder & President, ONCOtherapeutics
  • Founder & Principal, ONCOtracker
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Asymptomatic (smoldering/indolent) myeloma
  • solitary plasmacytoma of the bone
  • Extramedullary plasmacytoma
  • Light chain myeloma
  • Non-secretory myeloma
  • Osteosclerotic myeloma (POEMS syndrome)
  • Waldenstrom macroglobulinemia
  • Light chain amyloidosis
  • Plasma cell leukemia
  • Latest
  • Popular
  • Comments
  • Tags
  • James R. Berenson Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study February 8, 2022
  • Emory Universitys Big Discovery IMBCR & Emory University’s Big Discovery!!! February 7, 2022
  • Berenson Cancer Center James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center February 6, 2022
  • What Is Multiple Myeloma? January 10, 2019
  • Video Updates June 26, 2018
  • Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients February 16, 2011
  • The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo March 19, 2011
  • Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting November 23, 2011
  • Understanding Myeloma News About Secondary Cancers and Clotting May 28, 2012
  • Dedication of “Determination” Dedication of “Determination” June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma ASCO B-cell maturation antigen BCMA Biomarker Bortezomib bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory Carfilzomib Dedication HevyLite; immunoglobulins; multiple myeloma; outcomes IMBCR Kyprolis lenalidomide monoclonal antibodies more is not better Multiple Myeloma myeloma Overall survival Pomalyst proteasome inhibitors Revlimid Secondary Cancers TRAF6 transplant update

Links

  • American Cancer Society
  • American Society of Clinical Oncology
  • American Society of Hematology
  • Cancer Support Community
  • Institute for Myeloma & Bone Cancer Research
  • Leukemia & Lymphoma Society®
  • National Institutes of Health
  • Oncotherapeutics

Subscribe

Subscribe to our e-mail newsletter to receive updates.

Contact Us

9201 W. Sunset Blvd. Ste. 310
West Hollywood, CA 90069
Tel  (310) 623-1222
Fax (310) 623-1122
info@berensoncancercenter.com

Sunset Medical Plaza
© 2012-2018 James R. Berenson, MD, Inc. All rights reserved.
Privacy Policy | Sitemap
Scroll Up